Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
3(30%)
Results Posted
75%(3 trials)
Terminated
2(20%)

Phase Distribution

Ph not_applicable
1
10%
Ph phase_4
1
10%
Ph phase_2
3
30%
Ph phase_3
1
10%
Ph early_phase_1
1
10%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(3)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Active, not recruiting2
Terminated2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 31 (14.3%)
Phase 41 (14.3%)
N/A1 (14.3%)

Trials by Status

recruiting110%
active_not_recruiting220%
terminated220%
unknown110%
completed440%

Recent Activity

3 active trials
Showing 5 of 10
active_not_recruiting

CDK and Body Composition Study

NCT03697577
active_not_recruitingphase_2

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

NCT03789240
recruiting

Prospective 4D CTA of BAV Competence

NCT04645862
terminatedphase_2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677
terminatedphase_2

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

NCT04337827
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03697577

CDK and Body Composition Study

Active Not Recruiting
NCT03789240Phase 2

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Active Not Recruiting
NCT04645862

Prospective 4D CTA of BAV Competence

Recruiting
NCT06865677Phase 2

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

Terminated
NCT04337827Phase 2

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

Terminated
NCT03922828

Lung Nodule Prospective Database

Completed
NCT03764163Early Phase 1

Image and Model Based Analysis of Lung Disease

Completed
NCT02738346Phase 3

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

Unknown
NCT00500513Not Applicable

Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials

Completed
NCT00108615Phase 4

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

Completed

All 10 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
10